Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Blockbuster Competitors Figure Large Among Biosimilars Under Review in EU

Executive Summary

Amgen’s first biosimilar – a competitor to AbbVie’s Humira – and three would-be competitors to Amgen’s own Neulasta are among the 17 biosimilar products that are under evaluation at the European Medicines Agency.

Advertisement

Related Content

CHMP Readies ‘Outstanding Issues’ Lists For Products Nearing EU Review End
Amgen’s Biosimilar Adalimumab First To EU Nod But No Launch
Biosimilars Boost In Europe: 2017 Kicks Off With Three Approvals And Backing From ESMO
Biosimilars Get Bespoke Service: EMA To Pilot Tailored Scientific Advice
First Biosimilar MabThera One Step Away from EU Approval; Pegfilgrastim Filings Withdrawn
Amgen/Allergan Target Lucrative Avastin Market With Another Biosimilar Filing

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

PS119710

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel